ArticleCancer discovery2018
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 395 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
395citing papers in PubMed, 1 pooled it
50.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
395 citing papers in PubMed, 1 synthesis or guideline pooled it, 604 citations in OpenAlex.
- Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.Biochemical genetics · 2024Pooled it
- YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.Nature medicine · 2025Trial
- Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.Nature communications · 2025Trial
- Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.Nature communications · 2024Trial
- Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.Journal for immunotherapy of cancer · 2023Trial
- Article
- BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro.JTO clinical and research reports · 2026Article
- VISTA drives tumour-intrinsic proliferation in mesothelioma cells.British journal of cancer · 2026Article
- Article
- Review
- Article
- Insights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines.Thoracic cancer · 2026Article
- Brief report: attitudes and barriers toward genetic testing in pleural mesothelioma: a nationwide Italian survey.Familial cancer · 2026Article
- Research progress on the regulation of mesothelioma driven by deubiquitinating enzyme BAP1.Clinical and experimental medicine · 2026Review
- Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.Nature communications · 2026Article
- Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.Med (New York, N.Y.) · 2026Article
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma.NPJ precision oncology · 2026Article
- Divergent roles of PRR11 and HEPACAM in pleural mesothelioma: PRR11 as a prognostic biomarker and HEPACAM as a stage-associated gene with paradoxical expression.Translational cancer research · 2026Article
- The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.Current oncology reports · 2026Review
335 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
61 authors at 20 institutions in 10 countries.
Julija HmeljakDepartment of Pathology and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Francisco Sanchez-VegaMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Katherine A HoadleyDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0002-1216-477X
Juliann ShihThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Chip StewartDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID 0000-0003-2245-9552
David HeimanDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Patrick TarpeyCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
Ludmila DanilovaThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-2813-3094
Esther DrillDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Ewan A GibbGenomeDx Biosciences, Vancouver, British Columbia, Canada.
Reanne BowlbyCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Rupa KanchiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hatice U OsmanbeyogluComputational Systems Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yoshitaka SekidoDivision of Cancer Biology, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan.
Jumpei TakeshitaGenome Science Division, The University of Tokyo, Tokyo, Japan.
Yulia NewtonDepartment of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California, Santa Cruz, Santa Cruz, California.ORCID 0000-0002-6874-4335
Kiley GraimDepartment of Biomolecular Engineering and Center for Biomolecular Science and Engineering, University of California, Santa Cruz, Santa Cruz, California.
Manaswi GuptaThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Carl M GayDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lixia DiaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David L GibbsInstitute for Systems Biology, Seattle, Washington.
Vesteinn ThorssonInstitute for Systems Biology, Seattle, Washington.
Lisa IypeInstitute for Systems Biology, Seattle, Washington.
Havish KanthetiThe University of Texas at Dallas, Richardson, Texas.
David T SeversonDivision of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-1750-8332
Gloria RavegniniDepartment of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.ORCID 0000-0002-7774-402X
Patrice DesmeulesDepartment of Pathology, Quebec Heart and Lung Institute, Quebec, Canada.
Achim A JungbluthDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
William D TravisDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sanja DacicDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Lucian R ChirieacDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Françoise Galateau-SalléMESOPATH. Cancer Center Leon Berard, Lyon, France.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Aliya N HusainDepartment of Pathology, University of Chicago, Chicago, Illinois.
Henrique C SilveiraMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil.ORCID 0000-0001-8607-6206
Valerie W RuschDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert C RintoulDepartment of Oncology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-3875-3780
Harvey PassDepartment of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.
Hedy KindlerDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, Illinois.
Marjorie G ZaudererDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6109-5790
David J KwiatkowskiDivision of Pulmonary Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-5668-5219
Raphael BuenoDivision of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.
Anne S TsaoDepartment of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0505-6639
Jenette CreaneySchool of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia.
Tara LichtenbergThe Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Kristen LeraasThe Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Jay BowenThe Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
TCGA Research Network
Ina FelauNational Cancer Institute, Bethesda, Maryland.
Jean Claude ZenklusenNational Cancer Institute, Bethesda, Maryland.
Rehan AkbaniDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew D CherniackThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0003-0470-0111
Lauren A ByersDivision of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.
Michael S NobleThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.
Jonathan A FletcherDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
A Gordon RobertsonCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Ronglai ShenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Hiroyuki AburataniGenome Science Division, The University of Tokyo, Tokyo, Japan.
Bruce W RobinsonSchool of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia.
Peter CampbellCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
Marc LadanyiDepartment of Pathology and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. ladanyim@mskcc.org.
Memorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USBrigham and Women's Hospital · USBroad Institute · USInstitute for Systems Biology · USNationwide Children's Hospital · USUniversity of North Carolina at Chapel Hill · USNational Cancer Institute · USTokyo University of Science · JPUniversity of California, Santa Cruz · USUniversity of Pittsburgh Medical Center · USCanada's Michael Smith Genome Sciences Centre · CAThe University of Western Australia · AUAichi Cancer Center · JPGenome British Columbia · CAHospital de Câncer de Barretos · BRNYU Langone Health · USSidney Kimmel Comprehensive Cancer Center · USUniversity of Bologna · ITUniversity of Cambridge · GB
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MLarge Scale Genome SequencingU54HG003079 · NHGRI · WASHINGTON UNIVERSITY · PI DUTCHER, SUSAN K · 2004 to 2016
$445.7MX-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Human Genome Sequencing CenterU54HG003273 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A · 2004 to 2015
$341.3MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MGene Expression Patterns in Human Tumors Identified Using Transcript SequencingU24CA143848 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2009 to 2016
$20.8MGenome Characterization Center (GCC)U24CA143867 · NCI · BROAD INSTITUTE, INC. · PI GABRIEL, STACEY, MEYERSON, MATTHEW L. · 2009 to 2016
$17.0MThe Cancer Genome Atlas Data Analysis CenterU24CA143845 · NCI · BROAD INSTITUTE, INC. · PI CHIN, LYNDA, GETZ, GAD A · 2009 to 2016
$16.0MHarvard Genome Characterization CenterU24CA144025 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUCHERLAPATI, RAJU S. · 2009 to 2016
$14.0MThe USC-JHU Cancer Epigenome Characterization CenterU24CA143882 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BAYLIN, STEPHEN B., WEISENBERGER, DANIEL JOSEPH · 2009 to 2016
$13.3MMSKCC Center for Translational Cancer Genomic AnalysisU24CA143840 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC, SANDER, CHRIS · 2009 to 2016
$11.5MCancer transcriptome characterization using massively parallel DNA sequencingU24CA143866 · NCI · BRITISH COLUMBIA CANCER AGENCY · PI MARRA, MARCO ANTONIO · 2009 to 2015
$10.9MNCI NIH HHS K99 CA207871NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R00 CA207871NCI NIH HHS R01 CA120528NCI NIH HHS T32 CA009666NCI NIH HHS U24 CA143799NCI NIH HHS U24 CA143835NCI NIH HHS U24 CA143840NCI NIH HHS U24 CA143843NCI NIH HHS U24 CA143845NCI NIH HHS U24 CA143848NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA143866NCI NIH HHS U24 CA143867NCI NIH HHS U24 CA143882NCI NIH HHS U24 CA143883NCI NIH HHS U24 CA144025NCI NIH HHS U24 CA199461NCI NIH HHS U24 CA210950NCI NIH HHS U24 CA210969NCI NIH HHS U24 CA210990NHGRI NIH HHS T32 HG008345NHGRI NIH HHS U54 HG003067NHGRI NIH HHS U54 HG003079NHGRI NIH HHS U54 HG003273
Abstract
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of
Indexed as
MutationAgedBiomarkers, TumorFemaleHistone-Lysine N-MethyltransferaseHumansKaplan-Meier EstimateLung NeoplasmsMaleMesotheliomaMiddle AgedPleural NeoplasmsPrognosisProtein MethyltransferasesTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanBiomarkers, TumorHistone-Lysine N-MethyltransferaseProtein MethyltransferasesSETDB1 protein, humanTumor Suppressor ProteinsUbiquitin Thiolesterase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.